Intellia Therapeutics
Cambridge · Founded 2014
About Intellia Therapeutics
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex Vivo, and in vivo approaches. Intellia Therapeutics was formed in 2014 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Founded: 2014
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $1.5B
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2022)
- Ticker: nasdaq:NTLA
- Website: intelliatx.com
- Phone: (857) 285-6200
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/intellia-therapeutics-59213 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.